ANVISA: an introduction to a new regulatory agency with many challenges
| Autor: | Alexandra Beumer Sassi, Kim Huynh-Ba |
|---|---|
| Rok vydání: | 2018 |
| Předmět: |
medicine.medical_specialty
ANVISA Registration Pharmacology toxicology Pharmaceutical market lcsh:RS1-441 02 engineering and technology Public administration 01 natural sciences lcsh:Pharmacy and materia medica Health surveillance Public health surveillance Agency (sociology) medicine Public health lcsh:RM1-950 010401 analytical chemistry General Medicine 021001 nanoscience & nanotechnology Regulatory 0104 chemical sciences lcsh:Therapeutics. Pharmacology Regulatory agency Business Resolution 0210 nano-technology Brazil |
| Zdroj: | AAPS Open, Vol 4, Iss 1, Pp 1-6 (2018) |
| ISSN: | 2364-9534 |
| Popis: | Brazil, the largest country in South America, has become the second largest pharmaceutical market in the emerging world. The Brazillian Health Surveillance Agency (Agencia Nacional de Vigilancia Sanitaria - ANVISA) was created in 1999 with the primary goal to protect and promote public health surveillance over products and services in Brazil. The governing body and structure of this new regulatory agency will be the aims of this paper, where the authors hope to share their understanding on the regulatory processes and its significant importance of this agency. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink